Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 8/20 | 0.42 |
| ▸ | EDNRA | P25101 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8797162 | 0.89 | EDNRB (0.34) | EDNRBEDNRA | |
| SCHEMBL7336011 | 0.76 | SMN1; SMN2 (0.41) | MEN1KMT2ACYP3A4ALDH1A1VKORC1 | |
| SCHEMBL7342903 | 0.71 | SMN1; SMN2 (0.35) | MEN1KMT2AALDH1A1 | |
| SCHEMBL7344975 | 0.68 | HSP90AA1 (0.38) | EDNRBEDNRAALDH1A1HPGD | |
| SCHEMBL7068381 | 0.66 | EDNRB (0.51) | EDNRBEDNRAMEN1KMT2AALDH1A1 | |
| SCHEMBL7071220 | 0.63 | ALDH1A1 (0.54) | EDNRBEDNRAKMT2AALDH1A1HPGD | |
| SCHEMBL7339610 | 0.62 | HSP90AA1 (0.36) | EDNRBEDNRAMEN1KMT2AALDH1A1 | |
| SCHEMBL7068590 | 0.61 | ALDH1A1 (0.51) | EDNRBEDNRAKMT2AALDH1A1HPGD | |
| SCHEMBL8799145 | 0.61 | TARBP2 (0.31) | — | |
| SCHEMBL11459812 | 0.60 | ALDH1A1 (0.67) | MEN1KMT2ACYP3A4ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | DOOLEY DAVID JAMES (US) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | EDNRA, EDNRB, ECE1 | EDNRB 2/4885EDNRA 1/4885MEN1 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.